GSK Is Betting mRNA Can Kill Its Own Cash Cow

Traditional flu vaccines are made by growing the virus in fertilized chicken eggs. Yes, actual eggs. This process takes four to six months, which means manufacturers have to guess which flu strains will be circulating half a year before flu season even starts. Sometimes they guess right. Sometimes they don't. And when the virus mutates inside those eggs (a phenomenon called "egg-adaptive mutations"), the vaccine you get might not even match the strain it was designed to fight.

It's like ordering a winter coat in June based on a weather forecast. By the time December rolls around, the forecast may have changed completely.

mRNA vaccines flip this model. Because they're built from a genetic sequence rather than grown in biological systems, they can be designed and manufactured in weeks instead of months. Strain selection can happen much later in the season, which means better matching to whatever's actually circulating. No eggs, no egg-adaptive mutations, no guessing six months ahead.

Cell-based vaccines (like Seqirus's Flucelvax) split the difference: they avoid egg adaptation but still require growing virus in cell cultures, which is slower and less flexible than mRNA.

The Phase 2 Results That Gave GSK the Green Light

GSK didn't just waltz into Phase 3 on a hunch. The Phase 2 trial (called Flu-028) enrolled 971 adults across two age groups: 18–64 and 65 and older. Researchers compared two mRNA vaccine candidates against age-appropriate licensed flu vaccines in a randomized, observer-blind design.

The results were encouraging. GSK's optimized candidate produced higher immune responses against all tested influenza strains compared to both standard-dose vaccines (in younger adults) and high-dose vaccines (in older adults). The safety profile was described as acceptable, with follow-up through day 181 post-vaccination showing the vaccine was generally well tolerated.

Those are Phase 2 results, though, which means they measure immune responses (can your body make the right antibodies?) rather than real-world protection (do fewer vaccinated people actually get the flu?). Phase 3 is where the rubber meets the road. GSK hasn't disclosed the full trial design yet, including sample size, comparator vaccines, or specific endpoints.

A Strategic Gamble With the CEO's Fingerprints on It

This isn't just a science project. Analysts see the mRNA flu push as part of a broader strategy by GSK's new CEO to accelerate late-stage development ahead of looming patent cliffs. If key revenue streams are about to lose exclusivity, you need new products ready to fill the gap. An mRNA flu vaccine that outperforms legacy shots could be exactly that.

But Wall Street isn't throwing confetti yet. Analyst sentiment remains largely at Hold, which translates to: "We see what you're doing, but show us the Phase 3 data first." The key unknowns are still significant: clinical protection in a large efficacy trial, durability of the immune response, manufacturing scale, and pricing.

There's also the cannibalization math to consider. If GSK's mRNA flu vaccine proves meaningfully better, it could erode the company's own £408 million flu franchise. That's a feature, not a bug, if the mRNA version captures a larger slice of the overall market. But if Phase 3 stumbles, GSK will have spent years and significant resources attacking a product line that was, at worst, slowly declining.

The Bigger Picture: Eggs Are on Borrowed Time

Zoom out and the trend is unmistakable. Egg-based manufacturing still dominates flu vaccine production, accounting for over 69% of the market in 2025. But that number is shrinking. Cell-based vaccines are growing faster, and mRNA is arriving as the true disruptor.

GSK's decision to pursue Phase 3 is essentially a bet that the flu vaccine market is about to undergo the same transformation that COVID vaccines already proved was possible. Moderna has its approval. Pfizer is close. And now the biggest legacy flu vaccine maker in the world has decided it would rather disrupt itself than be disrupted.

The Phase 3 trial is planned for September 2026. If the data hold up, the era of cracking billions of eggs to make flu shots could be heading toward its expiration date. If they don't, GSK will have made the most expensive omelet in pharmaceutical history.